英科医疗 reported revenue of ¥6.91B for the period ended 2026-06-30, +40.6% year on year. Net income was ¥0.90B, a 13.1% net margin on a 37.8% gross margin. The largest revenue line is 个人防护类 at 90% of the total. Free cash flow for the period was ¥1.16B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥6.91B | +40.6% |
| Gross profit | ¥2.61B | — |
| Operating income | ¥1.10B | — |
| Net income | ¥0.90B | +24.5% |
| Gross margin | 37.8% | Net margin 13.1% |
| Revenue Q/Q | +39.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 个人防护类 | ¥6.19B | 89.7% |
| 其他产品 | ¥0.48B | 6.9% |
| 康复护理类 | ¥0.24B | 3.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥4.30B | 62.2% |
| R&D | ¥0.25B | 3.6% |
| SG&A | ¥0.55B | 8.0% |
| Tax & other | ¥0.19B | 2.8% |
| Item | Amount |
|---|---|
| Total assets | ¥41.24B |
| Total liabilities | ¥21.86B |
| Shareholders' equity | ¥19.39B |
| Equity / assets | 47.0% |
| Operating cash flow | ¥1.47B |
| Capital expenditure | ¥0.31B |
| Free cash flow | ¥1.16B |
| Cash conversion (OCF / net income) | 194% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物 ・ 中石科技 ・ 艾德生物 ・ 智动力 ・ 赛意信息 ・ 创业黑马 ・ 澄天伟业
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies